Phase I Study of Arabinosyl-5-zacytidine (Fazarabine) in Adult Acute Leukemia and Chronic Myelogenous Leukemia in Blastic Phase

Leukemia and Lymphoma

Volumn 34, Issue 42130, 1999, Pages 511-518

  Wilhelm, Martin ^a   Obrien, Susan ^b   Rios, Mary Beth ^b   Estey, Elihu ^b   Keating, Michael J ^b   Plunke‘it, William ^b   Sorenson, Mel ^c   Kantarjian, Hagop M ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

arabinosyl 5 zacytidine; fazarabine; leukemia acute; salvage therapy

Indexed keywords

FAZARABINE;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; LIVER TOXICITY; MAXIMUM PERMISSIBLE DOSE; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AZACITIDINE; BLAST CRISIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; REMISSION INDUCTION; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 0032842834     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428199909058478     Document Type: Article

References (35)

1. Mayer R J. Current chemotherapeutic treatment approaches to the management of previously untreated adults with de novo acute myelogenous leukemia. Sem Oncol 1987; 14: 384 – 96
2. Mayer R J, Davis R B, Schiffer C A, et al. Intensive post-remission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331: 896 – 903
3. Beisler J A, Abbasi M M, Driscoll J S. The synthesis and anti-tumor activity of arabinosyl-5 azacytosine. Biochem Pharmacol 1977; 26: 2469 – 72
4. Driscoll J S. The preclinical new drug research program of the National Cancer Institute. Cancer Treat Rep 1984; 68: 63 – 76
5. Townsend A, Leclerc J M, Dutschman G, Cooney D A, Cheng Y C. Metabolism of 1–β-D arabinosyl-5-zacytosine and incorporation into DNA of human T-lymphoblastic cells (Molt-4). Cancer Res 1985; 45: 3522 – 8
6. Glaser R I, Knode M C. l-β-D-arabinosyl-5-zacytosine: cytocidal activity and effects on the synthesis and methyla-tion of DNA in human colon carcinoma cells. Mol Pharmacol 1984; 26: 381 – 7
7. Veseiy J, Piskala A. Mechanism of action of I-β-D-ara-binofuranosyl-5-zacytosine and its effects in L 12 10 leukemia cells. Neoplasma 1986; 33: 3 – 10
8. Dalal M, Plowman J, Breitman T R, et al. Arabinofurano-syl-5-zacytosine: antitumor and cytotoxic properties. Cancer Res 1986; 46: 831 – 8
9. Zaharko D S, Covey J M. Arabinosyl-5-zacytosine: plasma kinetics and therapeutic.response (L 1210) in vitro and in vivo in mice. Invest New Drugs 1985; 3: 323 – 9
10. Driscoll J S, Johns D G, Plowman J. Comparison of the activity of arabinosyl-5-zacytosine, arabinosyl cytosine, and 5-zacytidine against intracellularly implanted L 1210 leukemia. Invest New Drugs 1985; 3: 3314
11. Grem J L, Shoemaker D D, Hoth D F, et al. Arabinosyl-5-za-cytosine: a novel nucleoside entering clinical trials. Invest New Drugs 1987; 5: 315 – 32
12. Wallace R E, Lindh D, Durr F E. Arabinosyl-5-zacytosine (ara-AC, fazarabine, NSC 281272) activity against human tumor xenografts. Proc Am Assoc Cancer Res 1987; 28: 307
13. Surbone A, Ford H, Kelley J A, et al. Phase I and pharmacok-inetic study of arabinofuranosyl 5-zacytosine (Fazarabine, NSC 281272). Cancer Res 1990; 50: 1220 – 5
14. Bennett J M, Catovsky D, Daniel M T, et al. Proposals for the classification of the acute leukemias. Br J Haematol 1976; 33: 451 – 8
15. National Cancer Institute. Guidelines for reporting of adverse drug reactions. Division of Cancer Treatment, National Cancer Institute, Bethesda, MD 1988
16. Notari R E, De Young J L. Kinetics and mechanisms of degradation of the antileukemic agent 5-zacytidine in aqueous solutions. J Pharm Sci 1975; 64: 1148 – 56
17. Mojaverian P, Repta A J. Development of an intravenous formulation of the unstable investigational cytotoxic nucleo-sides 5-zacvtosine arabinoside and 5-zacvtidine. J Pharm Pharmacol 1984; 36: 728 – 33
18. Estey E, Kornblau S, Pierce S, Kantarjian H, Beran M, Keating M. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood 1996; 88: 756
19. Glazer R, Knode M. I-β-D-Arabinosyl-5-acytosine. Cyto-cidal activity and effects on the synthesis and methylation of DNA in human colon carcinoma cells. Mol Pharmacol 1984; 26: 381 – 7
20. Kantarjian H M, Estey E H, Keating M A. New chemothera-peutic agents in acute myeloid leukemia. Leukemia 1996; 10 (Suppl 1) 4 – 6
21. Attadia V. Effects of 5-za-2-eoxycytidine on differentiation and oncogen expression in the human monoblastic leukemia cell line U-937. Leukemia 1993; 7 (Suppl 1) 9 – 16
22. Moore M, Andersen J, Bums H. A randomized trial of gem-citabine versus 5-U as first-line therapy in advanced pancreatic cancer. Proc Am Soc Clin 1995; 14: 199, abstr
23. Anderson F L, Lund B, Hansen H H, et al. Phase 11 study of gemcitabine in non-small cell lung cancer. Proc Am Soc Clin Oncol 1991; 10: 247, abstr
24. Smith T L, Lee J, Kantarjian H M, Legha S S, Raber M N. Design and results of phase I cancer clinical trials: three-year experience at M. D. Anderson Cancer Center. J Clin Oncol 1996; 14: 287 – 295
25. Estey E, Hoth D, Simon R, et al. Therapeutic response in phase I trials of antineoplastic agents. Cancer Treat Rep 1986; 70: 1105 – 1115
26. Penta J S, Rosner G L, Trump D L. Choice of starting dose and escalation for phase I studies of antitumor agents. Cancer Chemother Pharmacol 1992; 31: 247 – 250
27. Von Hoff D D, Turner J. Response rates, duration of response, and dose response effects in phase I studies of antineoplas-tics. Invest New Drugs 1991; 9: 115 – 122
28. O'Quigley J, Pepe M, Fisher L. Continual reassessment method A practical design for phase I clinical trials in cancer. Biometrics 1990; 46: 33 – 48
29. Gatsonis C, Greenhouse J B. Bayesian methods for phase I clinical trials. Stat Med 1992; 1: 1377 – 1389
30. Mick R, Lane N, Daugherty C, et al. Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I cancer trials. J Natl Cancer Inst 1994; 86: 1685 – 1693
31. O'Quigley J. Estimating the probability of toxicity at the recommended dose following a phase I clinical trial in cancer. Biometrics 1992; 48: 853 – 862
32. Chevret S. The continual reassessment method in cancer phase I clinical trials: A simulation study. Stat Med 1993; 12: 1093 – 1108
33. Goodman S N, Zahurak M, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat Med 1994; 13: 1 – 13
34. Collins J M, Grieshaber C K, Chabner B A. Pharmacologically guided phase I clinical trials based upon preclinical drug development. J Natl Cancer Inst 1990; 82: 1321 – 1326
35. Mick R, Ratain M J. Model-guided determination of maximum tolerated dose in phase I clinical trials: Evidence for increased precision. J Natl Cancer Inst 1993; 85: 217 – 223